Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Regeneron Pharmaceuticals
Woman and Man Max 99 years
Regeneron Pharmaceuticals, Inc
Update Il y a 4 ans
A study to determine the safety and tolerability of REGN668 in patients aged ≥6 to <18 years with atopic dermatitis (eczema)
The primary objective of the study is to characterize the safety and pharmacokinetics (PK) of dupilumab in pediatric patients with moderate-to-severe atopic dermatitis (AD) (for adolescents ≥12 to <18...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Regeneron Pharmaceuticals, Inc
Update Il y a 4 ans
A study to confirm the efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis (AD)
The primary objective of the study is to demonstrate the efficacy of dupilumab monotherapy compared to placebo treatment in adult patients with moderate-to-severe AD.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Regeneron Pharmaceuticals, Inc
Update Il y a 4 ans
A study to see if multiple doses of REGN668 given by injections under the skin is safe to use in adult patients with moderate-to-severe atopic dermatitis when given at the same time as topical corticosteroids
The primary objective of the study is to assess the safety of repeated subcutaneous (SC) doses of REGN668 administered concomitantly with topical corticosteroids (TCS) in adult patients with moderate-...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Regeneron Pharmaceuticals, Inc
Update Il y a 4 ans
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
The primary objective of this study is to estimate the clinical benefit of REGN2810 monotherapy for patients with metastatic (nodal or distant) CSCC (Group 1) or with unresectable locally advanced CSC...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Regeneron Pharmaceuticals, Inc
Update Il y a 4 ans
EFFICACY AND LONG TERM SAFETY STUDY OF DUPILUMAB IN ADULT PATIENTS WITH MODERATE0-TO-SEVERE ATOPIC DERMATITIS
Assess the efficacy of dupilumab over 12 weeks of treatment in adult patients with moderate-to-severe atopic dermatitis (AD) who have failed or are intolerant to topical steroids with or without topi...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
Regeneron Pharmaceuticals
Update Il y a 4 ans
Étude R2810-ONC-1620 : étude de phase 2 évaluant l’efficacité du REGN2810 chez des patients ayant un carcinome basocellulaire avancé ayant progressé sous thérapie par inhibiteurs de la voie Hedgehog, ou une intolérance à une thérapie antérieure par inhibiteurs de la voie Hedgehog. [Informations issues du site clinicaltrials.gov et traduites par l'INCa]
Les carcinomes sont les cancers de la peau les plus fréquents avec plus de 100 000 nouveaux cas annuels en France. Ils surviennent généralement après l'âge de 50 ans, sur les zones découvertes du corp...
Country
France
organs
Carcinomes cutanés
Specialty
Immunothérapie - Vaccinothérapie
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
Regeneron Pharmaceuticals, Inc
Update Il y a 4 ans
A study to confirm the efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis (AD)
The primary objective of the study is to demonstrate the efficacy of dupilumab monotherapy compared to placebo treatment in adult patients with moderate-to-severe AD.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Regeneron Pharmaceuticals, Inc
Update Il y a 4 ans
Efficacy and Safety of REGN727 added-on to Rosuvastatin versus Ezetimibe added-on to Rosuvastatin versus Rosuvastatin dose increase in patients who are not controlled on Rosuvastatin
To evaluate the reduction of LDL-C by REGN727 as add-on therapy to rosuvastatin in comparison with EZE as add-on therapy to rosuvastatin, and in comparison with doubling the rosuvastatin dose, after 2...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Regeneron Pharmaceuticals, Inc
Update Il y a 4 ans
A STUDY OF THE SAFETY AND EFFICACY OF REGN1033 UN ESTUDIO DE SEGURIDAD Y EFICACIA DE REGN1033
The primary objective of the study is to evaluate the effect of multiple doses of REGN1033 administered SC for 12 weeks on total lean body mass measured by DEXA in patients with sarcopenia. El o...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Regeneron Pharmaceuticals, Inc
Update Il y a 4 ans
A study to explore the safety and efficacy of alirocumab in patients that require Apheresis to control their blood lipid levels
The primary objective of the study is to evaluate the effect of alirocumab 150 mg every 2 weeks (Q2W) in comparison with placebo on the frequency of low-density lipoprotein (LDL) apheresis treatments ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3